Introduction
Severe acute kidney injury (AKI) occurs in 5-6% of all patients admitted to the intensive care unit (ICU) [1] . The use of renal replacement therapy (RRT) to treat patients with AKI represents a considerable escalation in both the complexity and cost of care and is associated with a mortality rate of ∼60% [1] [2] [3] [4] [5] [6] [7] . This is of particular importance since RRT is used to treat most patients with severe AKI [1] .
Despite its widespread use, there is minimal evidence to guide the optimal delivery of RRT for patients with severe AKI. Recent randomized controlled trials (RCTs) have better defined the acceptable minimum dose of RRT for patients with AKI [8, 9] ; however, uncertainty over many other aspects of RRT use in this setting remain, including the optimal timing of initiation [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] .
While there is limited data to suggest that earlier initiation of RRT may improve survival and recovery of renal function in critically ill patients with AKI [26] , no suitably designed RCT has addressed this question. A recent systematic review and meta-analysis of 15 studies concluded that there was insufficient evidence to enable a recommendation regarding the optimal timing of initiation [27] .
In the absence of high-quality evidence, it is unclear what factors practitioners consider important in the decision to initiate RRT for critically ill patients with severe AKI. To our knowledge, no study has previously been performed to delineate self-reported prescribing attitudes with respect to the timing of initiation of RRT for critically ill patients with AKI. We surveyed Canadian nephrologists and intensivists involved in the decision to initiate acute RRT for AKI in order to better understand the attitudes and behaviors that underlie RRT initiation.
Materials and methods

Survey population and setting
A web-based cross-sectional survey of Canadian intensivists and nephrologists was conducted between August and October 2010. The target sample was Canadian nephrologists and intensivists who prescribe RRT for AKI. The sample frame consisted of active members of either the Canadian Society of Nephrology (CSN) or the Canadian Critical Care Society (CCCS).
Survey design
The survey was designed with three sections. The first section included questions pertaining to demographic and practice characteristics. The second section assessed whether or not a series of biochemical and clinical factors were used as indications for the initiation of RRT and, if so, at what level the factor typically indicated the need for RRT. The third section consisted of three case-based scenarios. Scenario 1 involved a patient with AKI secondary to sepsis from a community-acquired pneumonia. In Scenario 2, a patient developed AKI following a motor vehicle crash with a closed head injury. In the final scenario, AKI occurred in the context of an acute ST elevation myocardial infarction (refer to the Supplementary materials for a detailed description of the scenarios). In each scenario, the severity of physiologic and biochemical variables potentially relevant to the initiation of RRT (e.g. electrolyte abnormalities, acid-base abnormalities, volume status, serum creatinine and urea and urine output) worsened at successive time points (A, B and C). At each time point, respondents were asked to indicate the most important reason why they would or would not start RRT. Questions to assess the influence of patient age and comorbidity, time-of-day and response to a loop diuretic challenge were also included.
The initial survey was reviewed for clarity, inclusion of factors relevant to the initiation of RRT and clinical sensibility, and revised based on the feedback of physicians at the University of Alberta. The final survey consisted of 17 questions, some of which were multipart. A copy of the final survey is available in the Supplementary material online.
Survey implementation
An invitation to complete the survey was distributed by e-mail to all members of the CSN and CCCS. This e-mail contained a link to the web-based questionnaire. To increase participation, reminder e-mails were sent out from the CSN and CCCS 4 weeks after initial responses had been received.
The Health Research Ethics Board of the co-ordinating study center at the University of Alberta approved this study prior to commencement.
Statistical analysis
Descriptive statistics were used to summarize the aggregated data. Continuous variables were summarized using means and SD, and categorical variables were summarized using frequencies and percentages.
Odds ratios (ORs) were used to describe the influence of additional factors on the timing of initiation of RRT for AKI, specifically, the timeof-day, response to a diuretic challenge, patient age and burden of comorbidity. For each scenario that presented an additional factor for consideration, ORs were calculated using the odds that respondents would initiate RRT after being made aware of the additional factor compared to their previous responses when that factor was not presented. The 95% confidence interval (CI) and P-value were then calculated using Fisher's exact test.
Differences in how nephrologists and intensivists reported using different variables when deciding the timing of initiation of RRT for AKI were summarized by dividing responses into three categories: initiation of RRT at a threshold below that of the overall median, initiation of RRT at a threshold equal to or above the overall median and those that indicated the variable is not used in making this decision. For each variable, differences between nephrologists and intensivists were then assessed using Fisher's exact test for 2 × 3 tables.
A P-value <0.05 (two tailed) was considered statistically significant with no adjustment for multiple testing.
All calculations were performed using SAS version 9.2 (SAS Institute, Cary, NC).
Results
We received 248 responses in total. After excluding 14 respondents who indicated they were not involved in prescribing RRT for AKI, 19 pediatricians, 15 working outside of Canada and 20 who completed less than the first five questions of the survey, there were 180 surveys included for analysis. Of those 180, 29 (22%) surveys did not have completed responses to the final question asking if respondents would be interested in participating in the conduct of an RCT assessing optimal timing of initiation of RRT for AKI.
Baseline characteristics of survey respondents are detailed in Table 1 . Responses were received from 96 (53%) nephrologists, 78 (43%) intensivists and 6 (3%) who reported combined practices. Respondents represented 32 different medical centers from across the country.
Self-reported thresholds for the initiation of RRT for AKI according to clinical and laboratory variables are reported in Table 2 .
Considering all respondents (n = 180), the factors most reported to be taken into consideration when deciding the timing of RRT for AKI were the serum potassium level, utilized by 175 (97%), and the degree of pulmonary edema, utilized by 176 (98%). In contrast, only 102 (57%) and 106 (59%) respondents reported consideration of serum creatinine and serum urea levels, respectively.
No respondents indicated that they would initiate RRT on the sole basis of an arterial pH >7.30, a serum urea <25 mmol/L, oliguria or diuretic-resistant oliguria with urine output ≥200 mL/12 h or mild peripheral edema. Otherwise, there was wide variation with respect to selfreported timing of initiation according to all the variables presented. Figure 1 summarizes the cumulative percentage of respondents that indicated they would initiate RRT at successive time points (A, B and C) for each of the three scenarios presented. Regardless of the scenario, there were respondents who indicated that they would start RRT at the lowest level of severity (Time point A) and those who indicated that they would not start RRT at the highest level of severity (Time point C).
Detailed responses to scenario-based questions are reported in Table S1 of the Supplementary materials available online. For all the scenarios, at none of the time points (A, B or C) that respondents could indicate whether they would initiate RRT, did >50% of respondents agree on a primary indication for initiation. Considering the three scenarios in aggregate, the most commonly cited reason for starting RRT was that of 'worsened oxygenation'. This accounted for 30% (112 of 374) of responses indicating that RRT should be initiated. The most commonly cited reason for not starting RRT was that the patient 'needs a fluid challenge first'. This comprised 41% (311 of 753) of all responses indicating that RRT would not be initiated.
Of the 178 respondents who completed at least a portion of the scenario-based questions, 36 (20%) indicated in their comments, at least once, that diuretics should be given prior to starting RRT for AKI. Of the 264 responses indicating that RRT should not be initiated for 'other' reasons, 84 (32%) specified that diuretics should be tried first. Table 3 reports the odds that additional information about a diuretic challenge and the time-of-day that clinical and laboratory results became known, and the patient's age and comorbidity status would alter the decision whether or not to start RRT for AKI.
RRT was less likely to be started after the patient was reported to have had a modest increase in urine output following the administration of a diuretic for at least 300 mL of urine output in the 12 h following a diuretic challenge (OR 0.51; 95% CI 0.31-0.85).
Respondents were significantly less likely to start RRT at 2:00 am (OR 0.28; 95% CI 0.15-0.53) or 4:00 am (OR 0.39; 95% CI 0.21-0.71) as opposed to when the time-ofday had not been provided. The lack of availability of RRT resources at night was commented on as the main reason for not starting RRT by 12 of 26 (46%) who had previously indicated they would start RRT when the timeof-day was not known.
Lastly, respondents were significantly less likely to indicate that they would initiate RRT when the patient was elderly, from a long-term care facility and had numerous comorbidities compared to when these details were not provided (OR 0.14; 95% CI 0.08-0.23). Of the 67 respondents who indicated that they would start RRT when age and comorbidities were unknown but not once they were specified, 39 (58%) commented that a family discussion was necessary before deciding and 21 (31%) indicated that RRT should be withheld due to the perception of medical futility. Of the 50 respondents who reported that they would still initiate RRT, only 6 (12%) made comments indicating that age and comorbidity should not influence the provision of RRT. Table 4 compares clinical features that were perceived as early triggers for RRT initiation among nephrologists and intensivists. 'Early' indications were defined according to values that were lower than the median threshold of all survey respondents that reported using a given variable. Nephrologists were less likely to start for early indications based on the laboratory variables of serum creatinine, serum urea and pH but more likely to start for early indications based on the clinical variables of oliguria, pulmonary and peripheral edema.
Of 135 respondents, 127 (94%) indicated that an RCT studying the timing of RRT for critically ill patients with AKI would be ethically justifiable. In addition, 115 (82%) of 141 respondents indicated that they would be interested in participating in such a trial.
Discussion
The factors that practitioners consider in deciding the timing of initiation of RRT for AKI are poorly characterized. Our survey, distributed broadly to Canadian nephrologists and intensivists involved in the decision to initiate RRT in critically ill patients, indicates that the most commonly considered factors are the serum potassium levels and the degree of pulmonary edema.
Regardless of which factors are considered to be relevant, the most striking finding of our survey relates to the diversity of self-reported prescribing practices and attitudes among survey respondents. When considering both self-reported thresholds for initiation of RRT for AKI as well as the reasons given for initiating or not initiating RRT in response to scenario-based questions, it is apparent that there is little agreement on what constitutes a trigger for initiation. Firstly, none of the minimum thresholds for initiation were agreed upon by >45% of those that reported that they utilized a particular variable when making this decision. Likewise, among those who indicated that they would start RRT at a particular time point in response to the scenario-based questions, there were no time points at which >50% of respondents agreed on the primary indication for starting. Lastly, regardless of the scenario, there were some respondents who indicated that they would not start RRT at the highest level of severity presented as well as those who indicated that they would start RRT at the lowest level of severity. A portion of the diversity of practice and attitudes regarding the timing of initiation of RRT for AKI may be accounted for by differences in how nephrologists and intensivists consider this clinical decision. Nephrologists in our survey were more likely than intensivists to report considering clinical rather than laboratory indications for initiation of RRT for AKI. They also had lower thresholds for initiation of RRT based on these factors compared with intensivists who also considered them in the decision-making process.
We believe our findings will aid in the design of a future prospective trial to address the issue of optimal timing of initiation of RRT for critically ill patients with AKI. Firstly, over 90% of respondents indicated that it would be ethical to conduct an RCT in which patients would be randomized to receive either early initiation of RRT or a more conservative strategy consistent with the current 'standard of care'. Likewise, the majority of respondents indicated willingness to participate in such a trial, implying that clinical equipoise exists for such a protocol. Secondly, any future trial must account for the considerable variation in self-reported thresholds for initiation of RRT described above. Inclusion criteria will need to be relatively simple and will necessitate the identification of patients with AKI who have an increased likelihood of subsequent progression requiring RRT initiation but have no immediate emergency indication. For example, our findings would suggest that patients with a serum potassium ≥6.0 μmol/L or a pH ≤7.2 would not be suitable for inclusion into a trial since most clinicians indicate RRT is immediately required on the basis of either finding. As such, the initial identification of eligible patients would ideally occur through the use of validated criteria, such as thresholds proposed by the consensus Risk, Injury, Failure, Loss, End-stage (RIFLE) kidney disease [28] or Acute Kidney Injury Network [29] classifications based on serum creatinine and urine output-based criteria, and possibly integrating the use of novel kidney injuryspecific biomarkers [30, 31] . One possibility is to then 'trigger' initiation for those randomized to the early arm once any of several widely considered variables reach a threshold level immediately below that of the self-reported median thresholds for initiation described by our study. For example, provided that there was no contrary biochemical or urine output-based evidence of improvement in AKI, a potassium ≥5.0 mmol/L, pH ≤7.30 or moderate pulmonary edema (after having been correlated experimentally with PaO 2 :FiO 2 ) could be all used as 'triggers'. As the thresholds themselves are somewhat arbitrary and may be too broad, observational studies that define clinical and laboratory characteristics of patients currently being started on RRT for AKI might help refine these triggers. Lastly, our findings provide insight into other barriers to randomization. These relate to clinicians' relative reluctance to initiate RRT for elderly patients with significant comorbidity (compared to younger patients with less comorbidity but identical clinical and laboratory findings) and for patients assessed in the middle of the night. It is critical to acknowledge these barriers and their potential impact upon trial feasibility, sample size estimation and broad acceptance of, and adherence to, a particular trial protocol. Table 3 . ORs for initiation of RRT for AKI following a specific modification to the clinical scenario compared to responses when that modification was not specified There were several noteworthy findings regarding the use of diuretics and volume overload in the context of AKI. It has been suggested that the use of loop diuretics for AKI may not be useful and is potentially harmful [32] [33] [34] [35] [36] [37] . While 67% of respondents indicated that they consider the degree of 'diuretic-resistant oliguria' in deciding when to start RRT, only 20% indicated that they would attempt a diuretic challenge prior to initiating RRT in response to scenario-based questions. In addition, 64% of respondents indicated that they would not start RRT on the basis of peripheral edema alone unless it was at least 'moderate to severe'. These findings seem to run counter to evolving evidence about the detrimental effects of volume overload [38, 39] (and possible benefits of loop diuretics in this context [39] ). Furthermore, it is inconsistent with the high frequency with which volume overload has previously been reported to be an indication for initiation of RRT in observational studies such as the Beginning and Ending Supportive Therapy for the kidney (BEST kidney) (37%) [40, 41] and the use of oliguria <400 mL/day as inclusion criteria (for 60% of the patients randomized) in the Randomized Evaluation of Normal versus Augmented Level (RENAL) Replacement Therapy Study [9] of RRT dosing in AKI.
Our study does have limitations that warrant discussion. Firstly, it is not possible from our data to discriminate how well clinicians' responses in the survey correlate with their 'real-world' behaviors and the degree to which responses are affected by peer-influenced expectations of what constitutes a 'socially correct' answer. However, respondents in our survey were anonymous (i.e. their identity was blinded to both peers and investigators) and we believe that this helped to mitigate such bias. Secondly, due to the large number of centers (32) represented (with the most responses from a single center being 21), a meaningful center-based analysis was not possible. While it may be that center-specific trends are an important influence upon the timing of RRT initiation for AKI, to our knowledge, no academic center in Canada has a center-specific policy regarding timing of initiation, and as such, we believe responses reasonably represent individual clinical beliefs, attitudes and practice preferences. Thirdly, our study is prone to bias due to 'undercoverage' based on our sampling frame. Theoretically, clinicians who prescribe RRT for AKI and are not members of either the CSN or CCCS could have prescribing practices that differ from their colleagues that are on the membership lists that we used to draw our sample. In addition, we may have received relatively more responses from clinicians with an interest in this issue compared with those who have little to no interest. Likewise, those with an interest in the optimal timing of RRT initiation may differ in their beliefs and prescribing practices. Finally, we were unable to obtain an accurate estimate of the number of eligible clinicians for our sampling frame. This has prevented us from presenting an overall response rate.
In conclusion, there is currently a wide range of practice with respect to the timing of RRT initiation for critically ill patients with AKI in Canada. This is coupled with a concurrent belief that a well-designed trial is needed to inform on this issue. Our findings suggest that future trials could benefit by focusing on early initiation triggers that are based upon variables that most commonly factor into the decision as to when to initiate RRT for AKI. Also, our results highlight that selected intangible variables (i.e. time-of-day, patient age and comorbidity status) strongly influence (and/or bias) the decision to start RRT for AKI and could impact enrollment and protocol adherence for critically ill patients randomized in a clinical trial of timing of initiation of RRT for AKI.
Supplementary data
Supplementary data are available online at http://ndt. oxfordjournals.org.
